(Q37127252)

18 August 2017

1 reference

title

Gene-modified bone marrow cell therapy for prostate cancer (English)

1 reference

18 August 2017

1 reference

1 reference

H Wang

1

1 reference

18 August 2017

T C Thompson

series ordinal

2

1 reference

18 August 2017

publication date

3 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

15

1 reference

18 August 2017

issue

10

1 reference

18 August 2017

page(s)

787-796

1 reference

Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

The intriguing role of polymorphonuclear neutrophils in antitumor reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Therapeutic potential of adult stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Adoptive T-cell therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Finding a place for tumor-specific T cells in targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

In vivo tracking of tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Tumor-associated macrophages in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

The origin and function of tumor-associated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Hypoxic regions exist in human prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Targeting tumour-associated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Genetically modified dendritic cells--a new, promising cancer treatment strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Genetically modified dendritic cells for therapeutic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Genetically modified dendritic cells for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Aberrant progenitors common to megakaryocytic and myeloid cells in a Down's infant with transient abnormal myelopoiesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Isolation of putative progenitor endothelial cells for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Marrow stromal cells as stem cells for nonhematopoietic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Muscle regeneration by bone marrow-derived myogenic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Derivation of pluripotent stem cells from cultured human primordial germ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Embryonic stem cell-derived glial precursors: a source of myelinating transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

RETRACTED: Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Myeloid lineage commitment from the hematopoietic stem cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Bone-marrow transplantation (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Gene therapy with drug resistance genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Hematopoietic stem cell gene therapy with drug resistance genes: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Immunological consequences of interleukin 12 administration after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Interleukin-12 (IL-12) gene therapy of leukemia: immune and anti-leukemic effects of IL-12-transduced hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Cell-based therapies and imaging in cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Endothelial progenitor cells' "homing" specificity to brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

How do stem cells find their way home?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Normal stem cells and cancer stem cells: the niche matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Induced pluripotent stem cell lines derived from human somatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Viral oncolysis for malignant liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Strategies for therapeutic targeting of the p53 pathway in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Current developments of immunotherapy in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

IL12, a direct stimulator and indirect inhibitor of haematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Immunotherapy of cancer by IL-12-based cytokine combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

mRTVP-1, a novel p53 target gene with proapoptotic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

The human glioma pathogenesis-related protein is structurally related to plant pathogenesis-related proteins and its gene is expressed specifically in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

RTVP-1, a novel human gene with sequence similarity to genes of diverse species, is expressed in tumor cell lines of glial but not neuronal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Differential expression of multiple unexpected genes during U937 cell and macrophage differentiation detected by suppressive subtractive hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Structure comparison of human glioma pathogenesis-related protein GliPR and the plant pathogenesis-related protein P14a indicates a functional link between the human immune system and a plant defense system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

IL-12 gene therapy of leukemia with hematopoietic progenitor cells without the toxicity of systemic IL-12 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Donor stem cells home to marrow efficiently and contribute to short- and long-term hematopoiesis after low-cell-dose unconditioned bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Dystrophin expression in the mdx mouse restored by stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

Gene therapy for cancer treatment: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Advances in preclinical investigation of prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.37

7 January 2021

Identifiers

DOI

10.1038/GT.2008.37

1 reference

18 August 2017

1 reference